Menu

What is the best time for postoperative radiation therapy in pN1 prostate cancer?

  • Free access

Francesco Mistretta, Stefano Luzzago,  Giulia Marvaso, Giulia Corrao, Ilaria Sabatini, Matteo Fontana, Federico Mastroleo, Mattia Zaffaroni, Maria Vincini, Ettore Di Trapani, Gabriele Cozzi, Roberto Bianchi, Matteo Ferro, Ottavio de Cobelli, Barbara Jereczek-Fossa, Gennaro Musi

Abstract:

We retrospectively compared long-term biochemical recurrence rates (BCR) in pN1 PCa patients that underwent adjuvant radiotherapy (aRT) vs. no aRT/early salvage (esRT) after robot-assisted radical prostatectomy and extended pelvic lymphadenectomy. All PCa pN1 M0 patients treated at a single high-volume center between 2010 and 2020 were analyzed. Patients with <10 LNs yield, or >10 positive LNs, or persistently detectable PSA after RARP were excluded. Kaplan-Meier (KM) plots depicted BCR rates. Multivariable Cox regression models (MCRMs) focused on predictors of BCR. The cumulative incidence plot depicted BCR rates after propensity score (PS) matching (ratio 1:1). 220 pN1 patients were enrolled, 133 (60.4%) treated with aRT and 87 (39.6%) with no-aRT/esRT. aRT patients were older, with higher rates of postoperative ISUP grade group 4-5, and higher rates of pT3b stage. The actuarial BCR was similar (aRT 39.8% vs. no-aRT/esRT 40.2%; p=1). Median time to BCR was 62 vs. 38 months in aRT vs. no-aRT/esRT patients (p=0.001). In MCRMs, patients managed with no-aRT/esRT were associated with higher rates of BCR over time (hazard ratio [HR]: 3.27, p<0.001). ISUP grade group 5 (HR: 2.18, p<0.01) was an independent predictor of BCR. In PS-matched cumulative incidence plots, the BCR rate was significantly higher in the aRT group (76.4 vs. 40.4%; p<0.01). Patients managed with no-aRT/esRT experienced BCR approximately two years before the aRT group. Despite, the important BCR benefit after aRT, this treatment strategy is underused in daily practice.

Received date: 04/03/2023

Accepted date: 06/22/2023

Ahead of print publish date: 06/30/2023

Issue: 3/2023

Volume: 70

Pages: 458 — 467

Keywords: prostate cancer, radiation therapy, prostatectomy, adjuvant radiotherapy, early salvage radiotherapy, biochemical recurrence

Supplementary files:
N182 Suppl TableS1-TE1.docx

DOI: 10.4149/neo_2023_230403N182

Pubmed

Shopping cart is empty